RAYNHAM, Mass.--(BUSINESS WIRE)--Medrobotics Corp., a medical robotics company, announced today it has received CE Mark regulatory clearance in Europe for colorectal applications with the Flex® Robotic System. Medrobotics is the first robotic company to offer minimally invasive, steerable and shapeable robotic products for colorectal procedures. With this expanded indication, the Flex® Robotic System becomes the first robotic surgical platform offering the ability to access hard to reach anatomy in both otolaryngology and colorectal procedures without the limits imposed by straight, rigid instruments.
“CE Mark for colorectal procedures is significant since it expands the number of patients who can be treated with the Flex® Robotic System and provides a true platform technology that multiple hospital departments can use,” said CEO Samuel Straface, Ph.D. “When combined with the unrivaled mobility of the system, European otolaryngology and colorectal surgeons can now perform minimally invasive surgery through the body’s natural orifices, offering the potential for truly scarless surgeries.”
"The Flex® Robotic System has been clinically proven to provide access and visualization to surgical targets in difficult to reach locations such as the oropharynx and endolarynx in otolaryngology,” said Dr. Marshall Strome, Professor and Chairman Emeritus, Cleveland Clinic Head and Neck Institute and Co-Chair of Medrobotics Medical Advisory Board. “With the new colorectal indication, more European surgeons, hospitals and patients can benefit from minimally invasive procedures,” added Strome.
The award-winning Flex® Robotic System has been widely recognized for advances in surgical robotic technology, including the Best-in-Show award at the 2016 Medical Design Excellence Awards (MDEA). Medrobotics’ Flex® Robotic System was designed to provide an affordable, easy-to-use and highly mobile robot-assisted surgical platform for hospitals and surgeons seeking to provide minimally-invasive treatment options to the broadest number of patients. Minimally invasive surgery has demonstrated advantages for patients and providers, such as shorter hospital stays and faster recovery times.
Medrobotics Corporation (www.Medrobotics.com) is a privately funded medical device company headquartered in Raynham, Massachusetts that manufactures and markets the Flex® Robotic System, the world’s first robotic surgical platform with a steerable and shapeable robotic scope. The Flex® Robotic System offers surgeons the unique ability to navigate complex anatomy minimally invasively and operate in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools. The Company’s vision is to provide more patients with access to minimally invasive surgery. Medrobotics received FDA clearance for the Flex® Robotic System in July 2015, and the CE mark in March 2014. The system is not yet cleared for colorectal applications in the US.